Tango Therapeutics, Inc. (TNGX) Stock Analysis

Q: What is the TNGX stock price target?

Take-profit $27.84 (+25.6% upside). Prior stop was $20.61.

Q: What are the risks of investing in TNGX?

Target reached (-6.2% upside); Quality below floor (2.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -9.4%), Material insider selling (9 sells, 0.05% of cap); Target reached (-6.2% upside); Quality below floor (2.0 < 4.0).

Q: Is TNGX overvalued or undervalued?

Tango Therapeutics, Inc. trades at a P/E of N/A (forward -13.3). TrendMatrix value score: 2.4/10. Overall verdict: Sell.

Q: What do analysts say about TNGX?

17 analysts cover TNGX with a consensus score of 4.3/5. Average price target: $24.

Range Bound setup

SellVALUE-TRAP 2/5High ConfidenceUpdated 2026-05-01

Healthcare · Biotechnology

Sell if holding. Engine safety override at $21.93: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10. Specifically: High short interest: 28%; Below-average business quality; Rich valuation.

$21.93+25.6% A.UpsideScore 3.6/10#156 of 158 Biotechnology

Stop $20.61Target $27.84(resistance)A.R:R -0.4:1

Analyst target$23.90+9.0%10 analysts

$27.84our TP

$21.93price

$23.90mean

$16

$40

Passes 4/7 gates (clean insider activity, no SEC red flags, news boost analyst 0.70, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Thesis

Rewards

Recent Analyst detected in news

Risks

Target reached (-6.2% upside)

Quality below floor (2.0 < 4.0)

Value-trap signals (2/5): Margin compression (op margin -9.4%), Material insider selling (9 sells, 0.05% of cap)

Key Metrics

P/E (TTM)—

P/E (Fwd)-13.3

Mkt Cap$3.1B

EV/EBITDA-26.0

Profit Mgn-162.9%

ROE-37.2%

Rev Growth-100.0%

Beta1.31

DividendNone

Rating analysts17

Quality Signals

Piotroski F2/9

Options Flow

P/C0.96neutral

IV190%elevated

Max Pain$7-68.1% vs spot

Material Events(8-K, last 90d)

2026-04-15Item 5.02MEDIUM
CFO Daniella Beckman departed effective April 15, 2026. Matthew Gall, 49, appointed CFO effective April 15, 2026. Previously CFO at Kalaris Therapeutics and iTeos Therapeutics. Annual base salary $540,000. Clean handoff.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value2.415%0.36

Quality2.015%0.30

Growth5.015%0.75

Momentum2.510%0.25

Sentiment7.710%0.77

Insider Activity3.410%0.34

Peer Rank0.610%0.06

Technical Setup6.35%0.32

Risk Profile2.05%0.10

Catalyst6.15%0.30

Overall (Σ contributions)3.55

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

0.0

Value Rank

0.7

Quality Rank

1.9

Unprofitable operations — net margin -162.9%. Quality floor flags this regardless of sector context.static

Roe

0.0

Roa

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -98% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Volatile — 8.2% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Implied Vol

0.0

Debt Equity

0.0

Short Interest

0.7

Max Pain Risk

3.0

Beta

5.7

Put Call

6.9

High short interest justified: 28%High IV: 190%Above max pain $7

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

0.0

Analyst Target

4.0

Expensive valuation

Low model confidence on this dimension (33%).

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd

0.0

Volume

0.0

Obv

1.0

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

GatesMomentum 2.5<4.5A.R:R -0.4=NEGATIVEEARNINGS PROXIMITY 10d<=14d (soft)Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70SEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

52 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $19.24Resistance $28.41

Price Targets

$21

$28

A.Upside+26.9%

A.R:R-0.4:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (-6.2% upside)

! Quality below floor (2.0 < 4.0)

! Value-trap signals (2/5): Margin compression (op margin -9.4%), Material insider selling (9 sells, 0.05% of cap)

Earnings

2/4 beats

Next Earnings2026-05-11 (10d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is TNGX stock a buy right now?

Sell if holding. Engine safety override at $21.93: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 3.6/10. Specifically: High short interest: 28%; Below-average business quality; Rich valuation. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $20.61. Score 3.6/10, high confidence.

What is the TNGX stock price target?

Take-profit target: $27.84 (+25.6% upside). Prior stop was $20.61. Stop-loss: $20.61.

What are the risks of investing in TNGX?

Target reached (-6.2% upside); Quality below floor (2.0 < 4.0); Value-trap signals (2/5): Margin compression (op margin -9.4%), Material insider selling (9 sells, 0.05% of cap).

Is TNGX overvalued or undervalued?

Tango Therapeutics, Inc. trades at a P/E of N/A (forward -13.3). TrendMatrix value score: 2.4/10. Verdict: Sell.

What do analysts say about TNGX?

17 analysts cover TNGX with a consensus score of 4.3/5. Average price target: $24.

What does Tango Therapeutics, Inc. do?Tango Therapeutics is a clinical-stage precision oncology company developing oral small molecule FGFR/PRMT5 inhibitors...

Tango Therapeutics is a clinical-stage precision oncology company developing oral small molecule FGFR/PRMT5 inhibitors for genetically defined cancers and rare diseases. Its lead program vopimetostat is in Phase 2 trials for urothelial cancers and achondroplasia; TNG456 (brain-penetrant GBM) and TNG260 (NSCLC) are in Phase 1/2. The company had an accumulated deficit of $603.2 million as of December 31, 2025.